🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Is Central Sensitization a Prognostic Indicator in Chronic Nonspecific Low Back Pain?

Recruitingn/aAges 18 Years - 65 YearsAllMardin Artuklu University
NCT07826546 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational study will examine whether signs of increased sensitivity in the nervous system at the beginning of the study are associated with short-term clinical outcomes in adults with chronic nonspecific low back pain. Approximately 180 participants will complete questionnaires about central sensitization, disability, pain, anxiety, and depression at the beginning of the study. After 6 weeks, disability, pain, and the participant's overall perception of change will be assessed again. The researchers will evaluate whether the initial level of central sensitization is associated with meaningful improvement in disability and perceived treatment benefit. Participants will not be assigned to a treatment as part of this study and will continue to receive routine clinical care.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 to 65 years * Diagnosis of chronic nonspecific low back pain lasting for at least 3 months * Willingness to participate in the study * Ability to provide written informed consent Exclusion Criteria: * Progressive neurological deficit * Inflammatory rheumatic disease * Active malignancy * History of serious spinal trauma or spinal surgery * Cognitive impairment that may prevent completion of the assessments or follow-up * Initiation, dose modification, or change of antidepressant or gabapentinoid treatment within the previous 3 months * Pregnancy, postpartum period, or breastfeeding * Inability to provide informed consent
💊

What it tests

  • Not listed
📍

Where

1 site
Mardin Training and Research Hospital
Mardin, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy